SCHEMBL191290

SCHEMBL191290

Cc1csc(Nc2cc(OC3CCCc4ccccc43)ccn2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.39
RAB9A P51151 3/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 2/20 0.39
MEN1 O00255 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
KCNN1 Q92952 1/20 0.39
KCNN2 Q9H2S1 1/20 0.39
KCNN3 Q9UGI6 1/20 0.39
GCK P35557 5/20 0.38
SLC2A1 P11166 1/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 3/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
NOX1 Q9Y5S8 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190625 0.79 GRM5 (0.51) TRPV4RAB9AKMT2ANPC1MEN1
SCHEMBL191227 0.76 TRPV4 (0.43) TRPV4RAB9AKMT2ANPC1MEN1
SCHEMBL191226 0.76 TRPV4 (0.43) TRPV4RAB9AKMT2ANPC1MEN1
SCHEMBL12305627 0.75 GCK (0.47) TRPV4KCNN1KCNN2KCNN3GCK
SCHEMBL192005 0.75 TRPV4 (0.47) TRPV4RAB9AKMT2ANPC1MEN1
Hydrochloric Acid SCHEMBL191575 0.74 GCK (0.46) TRPV4KCNN1KCNN2KCNN3GCK
SCHEMBL192164 0.74 ROCK1 (0.48) TRPV4
SCHEMBL2658979 0.74 TRPV4 (0.40) TRPV4RAB9AKMT2ANPC1MEN1
SCHEMBL190659 0.73 GCK (0.59) TRPV4RAB9AKMT2ANPC1MEN1
SCHEMBL191080 0.72 IDO1 (0.49) KMT2AMEN1ALDH1A1NOX1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 TRPV4 4775/4885RAB9A 1808/4885KMT2A 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.